- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04016012
Overweight and Obesity in Relation to Type ll Diabetes Melitus
September 16, 2022 updated by: Given Chipili, Mukuba University
Overweight and Obesity in Relation to Type II Melitus,Diabetes A Randomised Controlled Trial
The aim of the study is to evaluate the efficacy of local Zambian food in improving metabolic profiles of overweight/obese type ll diabetic patients in Kitwe district
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Given Chipili
- Phone Number: +26097874900
- Email: chipiligiven@yahoo.com
Study Contact Backup
- Name: Chiza Kumwenda
- Phone Number: +260974150967
- Email: chiza.kumwenda@unza.zm
Study Locations
-
-
Copperbelt
-
Kitwe, Copperbelt, Zambia, 50100
- Kitwe Teaching Hospital
-
Contact:
- Given Chipili
- Phone Number: +260978374900
- Email: chipiligiven@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diabetic patients attending Kitwe Teaching Hospital
- 18 years and above
- Body Mass Index of 25 and above
- Willing to follow the diet plan and eat food provided
- Not enrolled in other clinical studies
Exclusion Criteria:
- Eating disorder or any psychosocial or scheduling factors that could impede study outcomes
- Have renal or liver problem
- Pregnant women
- Breast feeding women
- HIV positive individuals
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
|
Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site.
The packs will be adjusted according to the weight of the participant and daily recommended allowances.
Packaging of foodstuffs will be done in the food service lab at the Mukuba University.
Instructions on how to prepare and use the food will be given to the participants.
All food Items will be labelled diabetic food to avoid intra-household sharing.
|
No Intervention: Control arm
The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Blood glucose levels
Time Frame: At baseline and 8 weeks
|
Fingertip blood sugar test using: blood glucose meter, test strips, lancet device, dry swabs, methylated spirit and a sharps box.
|
At baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body weight
Time Frame: At baseline and 8 weeks
|
Weight will be measured using the Seca adult scale
|
At baseline and 8 weeks
|
Change of Body Mass Index (BMI)
Time Frame: At baseline and 8 weeks
|
Hand held BMI machine will be used to determine the BMI of each participant.
|
At baseline and 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Given Chipili, Mukuba University, Kitwe, Zambia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 30, 2023
Primary Completion (Anticipated)
September 30, 2023
Study Completion (Anticipated)
October 15, 2023
Study Registration Dates
First Submitted
July 7, 2019
First Submitted That Met QC Criteria
July 9, 2019
First Posted (Actual)
July 11, 2019
Study Record Updates
Last Update Posted (Actual)
September 21, 2022
Last Update Submitted That Met QC Criteria
September 16, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MU0619
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Data collected in this study will be published online
IPD Sharing Time Frame
6 months after the study ends.
IPD Sharing Access Criteria
Mukuba University Website
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Local Zambian Foods
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingGut Microbiome | Linear GrowthUnited States
-
University of MiamiImmuno LaboratoriesCompleted
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingGut Microbiome | Neurodevelopment | Linear GrowthUnited States
-
Johns Hopkins UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Stanford UniversityActive, not recruitingInflammation | Pregnancy Related | Microbiome | Immune FunctionUnited States
-
The University of Tennessee, KnoxvilleCompletedMeasure Grams and Kcals of Snack Foods Consumed in Each ConditionUnited States
-
University of TorontoCompleted
-
Penn State UniversityCompleted
-
University of Wisconsin, MadisonBoston Children's HospitalCompletedPhenylketonuriaUnited States
-
University of VirginiaCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Disease | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Sickle Cell Disease | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myeloproliferative NeoplasmUnited States